[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648847":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":43,"locations":53,"responsibleParty":71,"collaborators":73,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":48,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":48,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":103,"whyStopped":48,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Lesaffre International","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-animal chondroitin sulfate","EXPERIMENTAL","The 10 selected volunteers will go to the PIC\u002FCIC in the morning on an empty stomach to determine the peak absorption (phase 1 - ingredient n°1) related to the ingestion of the MyCondro™ ingredient. Once the peak of absorption is known, the same 10 volunteers with the exception of study drop-out will be contacted for a second step of sampling (Phase 2) to collect both types of serum, a naive fraction (1) and a fraction enriched with metabolites of interest (2) at the time of peak absorption (blood samples (1) at t=0 before ingestion of the ingredient; (2) at t = peak absorption)",[13],"Dietary Supplement: MyCondro™",{"label":15,"type":16,"description":17,"interventionNames":18},"Animal-derived chondroitin sulfate","ACTIVE_COMPARATOR","The 10 selected volunteers will go to the clinical site in the morning on an empty stomach to determine the peak absorption (phase 1 - ingredient n°2) related to the ingestion of the Bovine chondroitin ingredient. Once the peak of absorption is known, the 10 volunteers with the exception of study drop-out will be contacted for a second step of sampling (Phase 2) to collect both type of serum, a naive fraction (1) and a fraction enriched with metabolites of interest (2) at the time of peak absorption (blood samples (1) at t=0 before ingestion of the ingredient ; (2) at t = peak absorption)",[19],"Dietary Supplement: Bovine chondroitin sulfate",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","MyCondro™","This is a non-animal chondroitin sulfate",[9],[27],"Ingredient n°1",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Bovine chondroitin sulfate","This is animal-derived chondroitin of bovine origin",[15],[33],"Ingredient n°2",[35,39],{"name":36,"affiliation":37,"role":38},"Gisèle PICKERING","Head of Department - Investigation Platform Clinical - CHU Clermont-Ferrand Clinical Investigation Center, Inserm CIC","PRINCIPAL_INVESTIGATOR",{"name":40,"affiliation":41,"role":42},"Yohann Wittrant","Scientific Coordinator Clinic'n'Cell - Faculty of Medicine and Pharmacy - Clermont-Ferrand - France","STUDY_DIRECTOR",[44,50],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Clinical Project Manager","CONTACT","+4915163496903",null,"v.oyedokun@gnosis.lesaffre.com",{"name":51,"role":46,"phone":48,"phoneExt":48,"email":52},"Director of Substantiation","y.fardini@gnosis.lesaffre.com",[54],{"facility":55,"status":48,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Centre d'investigation clinique | CIC","Clermont-Ferrand","Cedex 1","63003","France","FR",{"type":62,"coordinates":63},"Point",[64,65],3.08682,45.77969,{"lat":65,"lon":64},[68],{"name":69,"role":46,"phone":48,"phoneExt":48,"email":70},"Study Principal Investigator","gisele.pickering@uca.fr",{"type":72,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR",[74,77],{"name":75,"class":76},"Clinic'n'Cell","OTHER",{"name":78,"class":76},"University Hospital, Clermont-Ferrand","100648847","a-clinical-trial-evaluating-the-influence-of-the-ingredients-mycondro-and-bovine-chondroitin-sulfate-on-the-behavior-of-cells-in-the-osteoarticular-sphere-100648847",false,"NCT07727174","A Clinical Trial Evaluating the Influence of the Ingredients MyCondro™ and Bovine Chondroitin Sulfate on the Behavior of Cells in the Osteoarticular Sphere","Determination of the Biological Activity of Enriched Sera From Healthy Volunteers After Consumption of Chondroitin Sulfate of Both Animal and Fermentative Origin","Inclusion Criteria:\n\n* Men.\n* 18-35 years old (terminals included).\n* Liver test in the reference standards.\n* Renal assessment in the reference standards.\n* NFS in the reference standards.\n* CRP in the reference standards.\n* Blood pressure compatible with the conduct of the study.\n* Non-smoker or occasional smoker (\\\u003C5 cigarettes\u002Fday or \\\u003C 10ml per week of electronic cigarette liquid dosed at 3 mg\u002Fml of nicotine).\n* \\\u003C to 5 hours of intense sport per week.\n* Weight≥ to 60 kg.\n* BMI between 20 and 28 kg\u002Fm² (terminals not included).\n* Subjects able and willing to comply with the protocol and provide written informed consent.\n* Subjects affiliated to social security\n\nExclusion Criteria:\n\n* All types of vaccination under one month.\n* Alcohol consumption above WHO standards (\\>3 glasses of alcohol per day for men).\n* Ongoing treatment (medication, dietary supplement or probiotic) and within 4 weeks prior to inclusion.\n* Known pathology (including seasonal).\n* Allergy to the study product (all types)\n* People with a diet that is not suitable for the conduct of the study (e.g. vegetarian, vegan or vegan diet).\n* Change in eating habits in the 4 weeks prior to inclusion.\n* Medical and\u002For surgical history judged by the investigator or his\u002Fher representative to be incompatible with the trial.\n* Blood donation made in the 3 months prior to the inclusion visit or intending to do so during the study.\n* Persons under guardianship, curatorship, deprivation of liberty, safeguard of justice.\n* Refusal to sign the information sheet and consent.\n* Refusal to be registered on the National Register of Volunteers who lend themselves to research involving the human person.\n* Person who is excluded from another study on the national volunteer database, or who has received more than €6000 in the year following their participation in clinical studies.",true,"MALE","18 Years","35 Years",{"count":91,"type":92},10,"ESTIMATED","INTERVENTIONAL",[95],"NA","The study evaluates the effect of chondroitin sulfate derived from fermentation (MyCondro™) and bovine chondroitin sulfate, on the health and function of the skeletal system ex vivo, including cartilage, joint capsule, and bone tissue. The primary aim of the study is to determine the influence of human sera enriched with metabolites resulting from the ingestion of the ingredients on the metabolism of human primary cells of cartilage (chondrocytes), joint capsule (synoviocytes) and bone tissue (osteoblasts). Furthermore, the absorption kinetics of MyCondro™ and Bovine CS will be described.",[98],"Joint Health",[100,101,102,23],"Joint mobility","Joint health","non-animal chondroitin sulfate","NOT_YET_RECRUITING","2026-07-20",{"date":106,"type":107},"2026-07-27","ACTUAL",{"date":109,"type":92},"2026-08-26",{"date":111,"type":92},"2027-05",{"name":5,"class":6},1]